$5.61
8.41% today
Nasdaq, Apr 03, 06:28 pm CET
ISIN
US03476J1079
Symbol
ELTX
Sector
Industry

Angion Biomedica Corp Stock price

$5.17
-2.67 34.06% 1M
+0.13 2.58% 6M
+0.07 1.37% YTD
-2.25 30.32% 1Y
-17.13 76.82% 3Y
-165.03 96.96% 5Y
-165.03 96.96% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.22 4.44%
ISIN
US03476J1079
Symbol
ELTX
Sector
Industry

Key metrics

Market capitalization $82.48m
Enterprise Value $89.72m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-44.99m
Free Cash Flow (TTM) Free Cash Flow $-37.16m
Cash position $18.80m
EPS (TTM) EPS $-4.45
P/E forward negative
Short interest 1.23%
Show more

Is Angion Biomedica Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Angion Biomedica Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Angion Biomedica Corp forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a Angion Biomedica Corp forecast:

Buy
67%
Hold
33%

Financial data from Angion Biomedica Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 1.18 1.18
258% 258%
-
-1.18 -1.18
258% 258%
-
- Selling and Administrative Expenses 9.29 9.29
31% 31%
-
- Research and Development Expense 33 33
82% 82%
-
-44 -44
36% 36%
-
- Depreciation and Amortization 1.18 1.18
258% 258%
-
EBIT (Operating Income) EBIT -45 -45
38% 38%
-
Net Profit -52 -52
64% 64%
-

In millions USD.

Don't miss a Thing! We will send you all news about Angion Biomedica Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Angion Biomedica Corp Stock News

Neutral
GlobeNewsWire
3 days ago
Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis expected in Q3 2025
Neutral
GlobeNewsWire
10 days ago
BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer, effective as of the date hereof.

Company Profile

Angion Biomedica Corp. operates as a biopharmaceutical company. It focuses on the discovery and development of novel therapeutic agents to address acute organ injuries and fibrotic diseases. Its product pipeline includes ANG-3777, ANG-3070, ROCK2 Inhibitor and CYP11B2 Inhibitors. The company was founded by Itzhak D. Goldberg on April 06, 1998 and is headquartered in Uniondale, NY.

Head office United States
CEO Robert Connelly
Employees 32
Founded 2011
Website www.elicio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today